Business
This section features DDW articles on the business side of pharma & drug discovery.
Page 16 to 32 of 104 |   < PREVIOUS PAGE   NEXT PAGE >
Overcoming the Disruption Dip in the Aftermath of Mergers & Acquisitions By Roger Humphrey
M&A deals are disrupting the life science industry – and that’s good, mostly. Yet, when a company reshapes its facilities footprint in the wake of a consolidation, cost efficiency can be undermined by the dreaded ‘disruption dip’ in productivity. Here’s how to keep your workplaces and laboratories on track.

Read More

Therapeutic Drug Repurposing, Repositioning and Rescue Part II: Business Review By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld
There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable.

Read More

BioPharma and CROs Collaborating In Early Drug Discovery By Dr John Montana and Cornelis E.C.A. Hop
BioPharma and CROs are riding the latest wave - discovery research - together with a vigour and gusto that might have seemed implausible five years ago. How these collaborations are structured, and how well they function, can vary widely, though.

Read More

Misconduct in the biomedical sciences part 1: issues and causes By Dr Gerald H. Lushington and Rathnam Chaguturu
Science pursues truth. Real advances in biomedical sciences improve our quality of life and save lives, but the path to these advances is cluttered with the distraction of irreproducible results - an affliction that has reached epidemic proportions and is now a global crisis spanning developed and developing countries alike, with much of the problem arising from scientific misconduct.

Read More

Misconduct in the biomedical sciences part 2: detection and prevention By Dr Gerald H. Lushington and Rathnam Chaguturu
Discovering safe and effective medicines, one of the greatest gifts to humanity, relies intensely upon the availability of detailed, unassailably accurate biomedical scientific knowledge.

Read More

The Chinese Biologics Drug Market: Demand and Execution By Dr Andy Tsun, Jia Li, Joanne Sun, Dr Michael Yu, Dr Yajie Li and Xiaolin Liu
In the past decade, China's drug market has been expanding in double-digit percentages. This has brought about a huge increase in local drug makers and has lured multinational pharmaceutical companies to develop, manufacture and commercialise their drug products in China.

Read More

Building New Models of Drug Discovery in Europe - The Innovative Medicines Initiative By Dr Angela Wittelsberger, Dr Hugh Laverty and Dr Michel Goldman
The discovery and development of a new medicine is time-consuming, risky and expensive. It often takes 10-15 years and an investment of on average >$1 billion for a compound to navigate its way along the drug discovery and development process – and only 8% of drug candidates entering clinical development make it to market and benefiting the patient (2).

Read More

The Healthcare Industry's Evolving Role in Translational Research an Opportunity for Competitive Advantage By Gregory Venters
During the 20th century, medical research has observed enormous advances in basic science discovery, highlighted by the sequencing of the human genome.

Read More

How Pharma Companies Manage in a Tough Financial Climate By Paul Branthwaite
Maintaining knowledge and experience internally is a challenge in today's financial climate, in SMEs and in big pharma. This article provides some tips on how companies can maintain their best staff or find reliable alternative options, especially at the critical level, when downsizing is inevitable or 'class acts' are unavailable.

Read More

Implementing and Operating Large Complex Capital Projects in a Research Environment By Dr Tim Peakman
UK Biobank is a major UK study that will recruit 500,000 volunteers aged between 40 and 69 to provide a resource to study the link between genetic factors, environment and lifestyle in the causes of health and disease.

Read More

Changing the Model for Lab Equipment Maintenance and Asset Management By Martin Long
A large section of the Pharmaceutical, Biotech and supporting industries are currently driving aggressive cost-saving initiatives throughout their operations to remain competitive, and deliver shareholder value.

Read More

Lean Thinking for Drug Discovery – Better Productivity for Pharma By Dr Edward W. Petrillo
Success in drug discovery controls the success of the pharmaceutical enterprise. The molecular structure of every drug candidate, and the body of knowledge that will guide its use in the treatment of disease, are established during drug discovery in the iterative process known as lead optimisation.

Read More

India - Global pharmaceutical R&D powerhouse or contract research workshop? By Dr Matthew Howard
In response to the ever-increasing costs of drug discovery and development, pharmaceutical industry leaders must constantly seek to increase productivity while simultaneously reducing costs and maintaining quality.

Read More

Sharing Risks and Rewards - Basis for a turnkey pharma-biotech alliance in osteoarthritis Dr Andre Hoekema
In June 2006, Galapagos and GlaxoSmithKline’s Center of Excellence for External Drug Discovery (CEEDD) formed a multi-year worldwide alliance to discover and develop novel drugs for osteoarthritis.

Read More

The Art of Collaboration - Partnering and Licensing at Novartis By Anthony Rosenberg
Partnering and licensing have become paramount in a pharmaceutical industry that is under inordinate pressure to fill pipelines and increase the number of approved new molecular entities. This article discusses how Novartis has gone about addressing this issue.

Read More

Business
Page 16 to 32 of 104 |   < PREVIOUS PAGE   NEXT PAGE >